Who Gets to Do Research in Space When the International Space Station Is Gone?

Key Takeaways

• ISS retirement in 2030 ends 30-year multinational research platform
• Commercial stations will replace ISS, owned by private firms, not nations
• Public‑health labs risk displacement by tourism‑focused commercial priorities
• U.S. policy could fund research slots on private stations to safeguard science
• International partners must negotiate access agreements before commercial stations launch

Pulse Analysis

The International Space Station, a joint venture of NASA, Roscosmos, ESA, JAXA, CSA and others, will be retired in 2030 after three decades of orbiting research. Its aging modules, costly maintenance, and safety concerns have driven the decision to decommission the platform. In its place, a new generation of low‑Earth‑orbit habitats is being built by companies such as Axiom, SpaceX and Blue Origin, which will operate under commercial ownership rather than a multinational treaty. This marks the first time sovereign nations become customers rather than owners.

The ISS has functioned as a floating public‑health laboratory, enabling studies on bone loss, immune response, radiation exposure and telemedicine that translate to treatments on Earth. With commercial stations prioritizing tourism, manufacturing or profit‑driven experiments, the continuity of these biomedical programs is uncertain. Loss of a dedicated research venue could stall progress on countermeasures for long‑duration missions and diminish the pipeline of data that informs terrestrial health policies. Preserving a research mandate is therefore critical for both space exploration and domestic public‑health outcomes.

Policymakers can mitigate the risk by negotiating guaranteed research slots, subsidizing payload costs, or creating a public‑private research consortium that funds experiments on private habitats. The United States could leverage its existing contracts to require a minimum percentage of scientific payloads, while international partners can coordinate similar agreements to avoid a fragmented market. Such mechanisms would align commercial incentives with societal benefits, ensuring that the next era of orbital stations continues to serve as a testbed for medical innovation rather than solely a luxury destination.